For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Publications

Found 325 results
Author [ Title(Desc)] Type Year
Filters: Filter is   [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Wang C-E, Tydlacka S, Orr AL, Yang S-H, Graham RK, Hayden MR, Li S, Chan AWS, Li X-J.  2008.  Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease.. Hum Mol Genet. 17(17):2738-51.
Sohn PDongmin, Tracy TE, Son H-I, Zhou Y, Leite REP, Miller BL, Seeley WW, Grinberg LT, Gan L.  2016.  Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment.. Mol Neurodegener. 11(1):47.
Tracy TE, Gan L.  2017.  Acetylated tau in Alzheimer's disease: An instigator of synaptic dysfunction underlying memory loss: Increased levels of acetylated tau blocks the postsynaptic signaling required for plasticity and promotes memory deficits associated with tauopathy.. Bioessays. 39(4)
Caballero B, Bourdenx M, Luengo E, Diaz A, Sohn PDongmin, Chen X, Wang C, Juste YR, Wegmann S, Patel B et al..  2021.  Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice.. Nat Commun. 12(1):2238.
Tracy TE, Sohn PDongmin, S Minami S, Wang C, Min S-W, Li Y, Zhou Y, Le D, Lo I, Ponnusamy R et al..  2016.  Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss.. Neuron. 90(2):245-60.
Min S-W, Cho S-H, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C et al..  2010.  Acetylation of tau inhibits its degradation and contributes to tauopathy.. Neuron. 67(6):953-66.
Wang LY, Gan L, Perney TM, Schwartz I, Kaczmarek LK.  1998.  Activation of Kv3.1 channels in neuronal spine-like structures may induce local potassium ion depletion.. Proc Natl Acad Sci U S A. 95(4):1882-7.
Nicole O, Goldshmidt A, Hamill CE, Sorensen SD, Sastre A, Lyuboslavsky P, Hepler JR, McKeon RJ, Traynelis SF.  2005.  Activation of protease-activated receptor-1 triggers astrogliosis after brain injury.. J Neurosci. 25(17):4319-29.
Orr AG, Orr AL, Li X-J, Gross RE, Traynelis SF.  2009.  Adenosine A(2A) receptor mediates microglial process retraction.. Nat Neurosci. 12(7):872-8.
Sayed FA, Kodama L, Fan L, Carling GK, Udeochu JC, Le D, Li Q, Zhou L, Wong MYing, Horowitz R et al..  2021.  AD-linked R47H-TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation.. Sci Transl Med. 13(622):eabe3947.
Naseri NN, Ergel B, Kharel P, Na Y, Huang Q, Huang R, Dolzhanskaya N, Burré J, Velinov MT, Sharma M.  2020.  Aggregation of mutant cysteine string protein-α via Fe-S cluster binding is mitigated by iron chelators.. Nat Struct Mol Biol. 27(2):192-201.
Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC.  2010.  Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.. Science. 329(5999):1663-7.
Burré J, Beckhaus T, Schägger H, Corvey C, Hofmann S, Karas M, Zimmermann H, Volknandt W.  2006.  Analysis of the synaptic vesicle proteome using three gel-based protein separation techniques.. Proteomics. 6(23):6250-62.
Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul SM, Hyman BT et al..  2005.  Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice.. J Clin Invest. 115(2):428-33.
Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L et al..  2006.  Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease.. Neuron. 51(6):703-14.
DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'dell MA, Taylor JW, Harmony JAK, Aronow BJ, Bales KR, Paul SM et al..  2004.  ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.. Neuron. 41(2):193-202.
Shi Y, Yamada K, Liddelow SAntony, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC et al..  2017.  ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.. Nature. 549(7673):523-527.
Cao J, Gaamouch FEl, Meabon JS, Meeker KD, Zhu L, Zhong MB, Bendik J, Elder G, Jing P, Xia J et al..  2017.  ApoE4-associated phospholipid dysregulation contributes to development of Tau hyper-phosphorylation after traumatic brain injury.. Sci Rep. 7(1):11372.
Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V et al..  1999.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease.. Proc Natl Acad Sci U S A. 96(26):15233-8.
Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D et al..  2000.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.. Proc Natl Acad Sci U S A. 97(6):2892-7.
Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR et al..  2004.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.. Nat Med. 10(7):719-26.